A Virginia Board of Medicine emergency regulation regarding opioid prescribing has been modified to address sensitivity to naloxone when buprenorphine-naloxone products are prescribed.
The regulation now says that buprenorphine without naloxone, also called buprenorphine mono-product, may be prescribed for addiction treatment in patients who have a demonstrated intolerance to naloxone. But such prescriptions for the mono-product should account for less than 3% of the buprenorphine prescriptions written by a particular prescriber, and the exception must be documented in the patient's ...
Comments